

# GLOBAL MARKETS AND MANUFACTURING TECHNOLOGIES FOR PROTEIN DRUGS



**BIO021E**  
May 2016

Shalini Shahani Dewan  
*Project Analyst*

ISBN: 1-62296-288-5



**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481 USA  
866-285-7215 (toll-free within the USA),  
or (+1) 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
[information@bccresearch.com](mailto:information@bccresearch.com)

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	2
STUDY OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
CONTRIBUTIONS OF THE STUDY AND FOR WHOM	3
SCOPE OF THE STUDY	3
METHODOLOGY	3
INFORMATION SOURCES	3
ANALYSTS' CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	5
CHAPTER 2 EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE GLOBAL REVENUE FOR PROTEIN DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL REVENUE FOR PROTEIN DRUGS BY REGION, 2013-2020 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	10
HISTORY	10
<i>TABLE 1 EVOLUTION OF THERAPEUTIC PROTEINS</i>	10
PHARMACOLOGICAL CLASSIFICATION OF THERAPEUTIC PROTEINS	11
PROTEIN THERAPEUTICS WITH ENZYMATIC OR REGULATORY ACTIVITY	12
By Replacing the Deficient or Abnormal Protein	12
By Augmenting an Existing Pathway	12
By Providing a Novel Function or Activity	12
PROTEIN THERAPEUTICS WITH SPECIAL TARGETING ACTIVITY	13
Interfering with a Molecule or Organism	13
Delivering Other Compounds or Proteins	13
PROTEIN VACCINES	13
MOLECULAR CLASSIFICATION OF THERAPEUTIC PROTEINS	13
CYTOKINES	14
Interferons	14
Interleukins	14
Colony Stimulating Factors	15
MONOCLONAL ANTIBODIES	15
BLOOD PRODUCTS	16
Alpha 1 Proteinase Inhibitor	16
Anti-Hemophilic Factor	16
Anti-Thrombin	16
C1-Esterase Inhibitor	17
Coagulation Factors	17
Immuno Globulins	17
Protein C	18
Thrombin	18
PEPTIDE ANTIBIOTICS	18

<b>TOPIC</b>	<b>PAGE NO.</b>
VACCINES	18
Live, Attenuated Vaccines	19
Inactivated/Killed Vaccines	19
Toxoid	19
Subunit/Conjugate	19
ENZYMES	20
Digestive Enzymes	20
Metabolic Enzymes/Lysosomal Enzymes	20
Other Enzymes	21
PEPTIDE HORMONES	21
Follicle Stimulating Hormone and Luteinizing Hormone	22
Growth Hormones	22
Erythropoietin	22
Insulin	22
MANUFACTURING TECHNOLOGIES	23
FRACTIONATION/ EXTRACTION FROM NATURAL SOURCES (HUMAN/ANIMAL)	23
TABLE 2 PROTEIN DRUGS MADE BY FRACTIONATION	24
MICROBIAL FERMENTATION AND BIOREACTORS	25
Bioreactors	25
TABLE 3 THERAPEUTIC DRUGS PRODUCED BY MICROBIAL FERMENTATION	25
TRANSGENICS	26
TABLE 4 PROTEIN DRUGS PRODUCED BY TRANSGENIC ANIMALS, PLANTS AND MICROORGANISMS	26
MAMMALIAN CELL CULTURE	27
TABLE 5 PROTEIN DRUGS MADE BY CELL CULTURE	27
CHAPTER 4 REGULATORY ASPECTS	29
MONOCLONAL ANTIBODIES	29
TABLE 6 NEW APPROVALS OF MONOCLONAL ANTIBODIES, 2013-OCTOBER 2015	29
THERAPEUTIC ENZYMES	30
TABLE 7 NEW APPROVALS IN THERAPEUTIC ENZYMES, 2013-OCTOBER 2015	31
CYTOKINES	31
TABLE 8 NEW APPROVALS OF CYTOKINES, 2013-OCTOBER 2015	31
PEPTIDE HORMONES	31
TABLE 9 NEW APPROVALS OF PEPTIDE HORMONES, 2013-OCTOBER 2015	32
VACCINES	32
TABLE 10 NEW APPROVALS OF VACCINES, 2013-OCTOBER 2015	33
BLOOD PRODUCTS	34
TABLE 11 NEW APPROVALS OF BLOOD PRODUCTS, 2013-OCTOBER 2015	34
PEPTIDE ANTIBIOTICS	36
TABLE 12 NEW APPROVALS OF PEPTIDE ANTIBIOTICS, 2013-OCTOBER 2015	36
RECALLS	36
TABLE 13 RECALLS, 2013-OCTOBER 2015	37
SAFETY ALERTS	39
TABLE 14 SAFETY ALERTS, 2013-OCTOBER 2015	39
CHAPTER 5 NEW DEVELOPMENTS	42
MONOCLONAL ANTIBODIES	42

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 15 PIPELINE PRODUCTS OF MONOCLONAL ANTIBODIES</i>	42
VACCINES	47
<i>TABLE 16 PIPELINE PRODUCTS OF VACCINES</i>	48
CYTOKINES	49
<i>TABLE 17 PIPELINE PRODUCTS OF CYTOKINES</i>	50
PEPTIDE HORMONES	50
<i>TABLE 18 PIPELINE PRODUCTS IN PEPTIDE HORMONES</i>	50
PEPTIDE ANTIBIOTICS	51
<i>TABLE 19 PIPELINES IN PEPTIDE ANTIBIOTICS</i>	51
THERAPEUTIC ENZYMES	52
<i>TABLE 20 PIPELINE PRODUCTS IN THERAPEUTIC ENZYMES</i>	52
BLOOD PRODUCTS	53
<i>TABLE 21 PIPELINE PRODUCTS IN BLOOD PRODUCTS</i>	53
MERGERS AND ACQUISITIONS	53
<i>TABLE 22 MERGERS AND ACQUISITIONS OF TOP PHARMACEUTICAL COMPANIES</i>	54
CHAPTER 6 MARKET ANALYSIS BY TYPE	57
MARKET BY TYPE	57
MARKET OVERVIEW	58
MARKET REVENUE	58
<i>TABLE 23 GLOBAL REVENUE FOR PROTEIN DRUGS BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	59
<i>FIGURE 1 GLOBAL REVENUE FOR PROTEIN DRUGS BY TYPE, 2013-2020 (\$ MILLIONS)</i>	59
MARKET SHARE	60
<i>TABLE 24 MARKET SHARE OF PROTEIN DRUGS BY TYPE, 2014 (%)</i>	60
<i>FIGURE 2 MARKET SHARE OF PROTEIN DRUGS BY TYPE, 2014 (%)</i>	60
PEPTIDE HORMONES	61
Market Overview	62
Market Revenue	62
<i>TABLE 25 GLOBAL REVENUE FOR PEPTIDE HORMONES BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	63
<i>FIGURE 3 GLOBAL REVENUE FOR PEPTIDE HORMONES BY TYPE, 2013-2020 (\$ MILLIONS)</i>	63
VACCINES	64
Market Overview	64
Market Revenue	66
<i>TABLE 26 GLOBAL REVENUE FOR VACCINES BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	66
<i>FIGURE 4 GLOBAL REVENUE FOR VACCINES BY TYPE, 2013-2020 (\$ MILLIONS)</i>	67
THERAPEUTIC ENZYMES	67
Market Overview	67
Market Revenue	69
<i>TABLE 27 GLOBAL REVENUE FOR THERAPEUTIC ENZYMES BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	69
<i>FIGURE 5 GLOBAL REVENUE FOR THERAPEUTIC ENZYMES BY TYPE, 2013-2020 (\$ MILLIONS)</i>	69
MONOCLONAL ANTIBODIES	70
Market Overview	71
Market Revenue	72

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 28 GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	73
<i>FIGURE 6 GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY TYPE, 2013-2020 (\$ MILLIONS)</i>	74
CYTOKINES	74
Market Overview	75
Market Revenue	75
<i>TABLE 29 GLOBAL REVENUE FOR CYTOKINES BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	76
<i>FIGURE 7 GLOBAL REVENUE FOR CYTOKINES BY TYPE, 2013-2020 (\$ MILLIONS)</i>	77
BLOOD FACTORS	77
Market Overview	78
Market Revenue	79
<i>TABLE 30 GLOBAL REVENUE FOR BLOOD FACTORS BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	79
<i>FIGURE 8 GLOBAL REVENUE FOR BLOOD FACTORS BY TYPE, 2013-2020 (\$ MILLIONS)</i>	79
PEPTIDE ANTIBIOTICS	80
Market Overview	80
Market Revenue	81
<i>TABLE 31 GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	82
<i>FIGURE 9 GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY TYPE, 2013-2020 (\$ MILLIONS)</i>	82
MARKET BY REGION	82
MARKET OVERVIEW	83
MARKET REVENUE	84
<i>TABLE 32 GLOBAL REVENUE FOR PROTEIN DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	85
<i>FIGURE 10 GLOBAL REVENUE FOR PROTEIN DRUGS BY REGION, 2013-2020 (\$ MILLIONS)</i>	85
MARKET SHARE	86
<i>TABLE 33 MARKET SHARE OF PROTEIN DRUGS BY REGION, 2014 (%)</i>	86
<i>FIGURE 11 MARKET SHARE OF PROTEIN DRUGS BY REGION, 2014 (%)</i>	86
PEPTIDE HORMONES	86
Market Overview	87
Market Revenue	88
<i>TABLE 34 GLOBAL MARKET FOR PEPTIDE HORMONES BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	88
<i>FIGURE 12 GLOBAL MARKET FOR PEPTIDE HORMONES BY REGION, 2013-2020 (\$ MILLIONS)</i>	89
VACCINES	89
Market Overview	89
Market Revenue	90
<i>TABLE 35 GLOBAL REVENUE FOR VACCINES BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	91
<i>FIGURE 13 GLOBAL REVENUE FOR VACCINES BY REGION, 2013-2020 (\$ MILLIONS)</i>	91
THERAPEUTIC ENZYMES	91
Market Overview	92
Market Revenue	92

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 36 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	93
<i>FIGURE 14 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY REGION, 2013-2020 (\$ MILLIONS)</i>	93
MONOCLONAL ANTIBODIES	93
Market Overview	94
Market Revenue	94
<i>TABLE 37 GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	95
<i>FIGURE 15 GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY REGION, 2013-2020 (\$ MILLIONS)</i>	95
CYTOKINES	96
Market Overview	96
Market Revenue	96
<i>TABLE 38 GLOBAL REVENUE FOR CYTOKINES BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	97
<i>FIGURE 16 GLOBAL REVENUE FOR CYTOKINES BY REGION, 2013-2020 (\$ MILLIONS)</i>	98
BLOOD FACTORS	98
Market Overview	98
Market Revenue	99
<i>TABLE 39 GLOBAL REVENUE FOR BLOOD FACTORS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	99
<i>FIGURE 17 GLOBAL REVENUE FOR BLOOD FACTORS BY REGION, 2013-2020 (\$ MILLIONS)</i>	99
PEPTIDE ANTIBIOTICS	100
Market Overview	100
Market Revenue	101
<i>TABLE 40 GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	101
<i>FIGURE 18 GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY REGION, 2013-2020 (\$ MILLIONS)</i>	101
CHAPTER 7 MARKET ANALYSIS BY MANUFACTURING PROCESS	104
MARKET BY MANUFACTURING PROCESS	104
MARKET OVERVIEW	105
MARKET REVENUE	106
<i>TABLE 41 GLOBAL REVENUE FOR PROTEIN DRUGS BY MANUFACTURING PROCESS, THROUGH 2020 (\$ MILLIONS)</i>	106
<i>FIGURE 19 GLOBAL REVENUE FOR PROTEIN DRUGS BY MANUFACTURING PROCESS, 2013-2020 (\$ MILLIONS)</i>	106
MARKET SHARE	107
<i>TABLE 42 MARKET SHARE OF PROTEIN DRUGS BY MANUFACTURING PROCESS, 2014 (%)</i>	107
<i>FIGURE 20 MARKET SHARE OF PROTEIN DRUGS BY MANUFACTURING PROCESS, 2014 (%)</i>	108
PEPTIDE HORMONES	108
Market Overview	109
Market Revenue	109
<i>TABLE 43 GLOBAL REVENUE FOR PEPTIDE HORMONES BY MANUFACTURING PROCESS, THROUGH 2020 (\$ MILLIONS)</i>	110

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 21 GLOBAL REVENUE FOR PEPTIDE HORMONES BY MANUFACTURING PROCESS, 2013-2020 (\$ MILLIONS)</i>	110
VACCINES	111
Market Overview	111
Market Revenue	112
<i>TABLE 44 GLOBAL REVENUE FOR VACCINES BY MANUFACTURING PROCESS, THROUGH 2020 (\$ MILLIONS)</i>	112
<i>FIGURE 22 GLOBAL REVENUE FOR VACCINES BY MANUFACTURING PROCESS, 2013-2020 (\$ MILLIONS)</i>	112
THERAPEUTIC ENZYMES	113
Market Overview	114
Market Revenue	114
<i>TABLE 45 GLOBAL REVENUE FOR THERAPEUTIC ENZYMES BY MANUFACTURING PROCESS, THROUGH 2020 (\$ MILLIONS)</i>	115
<i>FIGURE 23 GLOBAL REVENUE FOR THERAPEUTIC ENZYMES BY MANUFACTURING PROCESS, 2013-2020 (\$ MILLIONS)</i>	115
MONOCLONAL ANTIBODIES	115
Market Overview	116
Market Revenue	117
<i>TABLE 46 GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, THROUGH 2020 (\$ MILLIONS)</i>	117
<i>FIGURE 24 GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, 2013-2020 (\$ MILLIONS)</i>	117
CYTOKINES	118
Market Overview	118
Market Revenue	119
<i>TABLE 47 GLOBAL REVENUE FOR CYTOKINES BY MANUFACTURING PROCESS, THROUGH 2020 (\$ MILLIONS)</i>	119
<i>FIGURE 25 GLOBAL REVENUE FOR CYTOKINES BY MANUFACTURING PROCESS, 2013-2020 (\$ MILLIONS)</i>	120
BLOOD FACTORS	120
Market Overview	120
Market Revenue	121
<i>TABLE 48 GLOBAL REVENUE FOR BLOOD FACTORS BY MANUFACTURING PROCESS, THROUGH 2020 (\$ MILLIONS)</i>	122
<i>FIGURE 26 GLOBAL REVENUE FOR BLOOD FACTORS BY MANUFACTURING PROCESS, 2013-2020 (\$ MILLIONS)</i>	122
PEPTIDE ANTIBIOTICS	122
Market Overview	123
Market Revenue	123
<i>TABLE 49 GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY MANUFACTURING PROCESS, THROUGH 2020 (\$ MILLIONS)</i>	124
<i>FIGURE 27 GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY MANUFACTURING PROCESS, 2013-2020 (\$ MILLIONS)</i>	124
CHAPTER 8 INDUSTRY STRUCTURE	126
PEPTIDE HORMONES	126
MARKET LEADERS	126
<i>TABLE 50 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE HORMONES, 2014</i>	126
MARKET SHARE	128

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 51 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE HORMONES, 2014 (%)</i>	128
<i>FIGURE 28 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE HORMONES, 2014 (%)</i>	128
VACCINES	129
MARKET LEADERS	129
<i>TABLE 52 LEADING MANUFACTURERS/SUPPLIERS OF VACCINES, 2014</i>	129
MARKET SHARE	132
<i>TABLE 53 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR VACCINES, 2014 (%)</i>	132
<i>FIGURE 29 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR VACCINES, 2014 (%)</i>	133
THERAPEUTIC ENZYMES	133
MARKET LEADERS	133
<i>TABLE 54 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC ENZYMES, 2014</i>	133
MARKET SHARE	134
<i>TABLE 55 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR THERAPEUTIC ENZYMES, 2014 (%)</i>	135
<i>FIGURE 30 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR THERAPEUTIC ENZYMES, 2014 (%)</i>	135
MONOCLONAL ANTIBODIES	136
MARKET LEADERS	136
<i>TABLE 56 LEADING MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2014</i>	136
MARKET SHARE	137
<i>TABLE 57 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2014 (%)</i>	137
<i>FIGURE 31 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2014 (%)</i>	138
CYTOKINES	138
MARKET LEADERS	138
<i>TABLE 58 LEADING MANUFACTURERS/SUPPLIERS OF CYTOKINES, 2014</i>	138
MARKET SHARE	139
<i>TABLE 59 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR CYTOKINES, 2014 (%)</i>	139
<i>FIGURE 32 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR CYTOKINES, 2014 (%)</i>	139
BLOOD FACTORS	140
MARKET LEADERS	140
<i>TABLE 60 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC BLOOD PRODUCTS, 2014</i>	141
MARKET SHARE	143
<i>TABLE 61 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR RECOMBINANT BLOOD PRODUCTS, 2014 (%)</i>	143
<i>FIGURE 33 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR RECOMBINANT BLOOD PRODUCTS, 2014 (%)</i>	144
PEPTIDE ANTIBIOTICS	144
MARKET LEADERS	144
<i>TABLE 62 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE ANTIBIOTICS, 2014</i>	144



<b>TOPIC</b>	<b>PAGE NO.</b>
MARKET SHARE	145
<i>TABLE 63 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE ANTIBIOTICS, 2014 (%)</i>	145
<i>FIGURE 34 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE ANTIBIOTICS, 2014 (%)</i>	145
CHAPTER 9 PATENT ANALYSIS	148
PATENTS BY YEAR	148
<i>TABLE 64 NUMBER OF PATENTS BY YEAR, 2013-OCTOBER 2015</i>	149
<i>FIGURE 35 NUMBER OF PATENTS BY YEAR, 2013-OCTOBER 2015</i>	149
PATENTS BY TYPE	149
<i>TABLE 65 NUMBER OF PATENTS BY TYPE, 2013-OCTOBER 2015</i>	149
<i>FIGURE 36 NUMBER OF PATENTS BY TYPE, 2013-OCTOBER 2015</i>	150
PATENTS BY COMPANY	150
<i>TABLE 66 NUMBER OF PATENTS BY COMPANY, 2013-OCTOBER 2015</i>	151
PATENTS BY COUNTRY	154
<i>TABLE 67 NUMBER OF PATENTS BY COUNTRY, 2013-OCTOBER 2015</i>	155
<i>TABLE 68 PATENT SHARES BY COUNTRY, 2013-OCTOBER 2015 (%)</i>	156
<i>FIGURE 37 PATENT SHARES BY COUNTRY, 2013-OCTOBER 2015 (%)</i>	156
PATENTS BY ASSIGNEE	157
<i>TABLE 69 NUMBER OF PATENTS BY ASSIGNEE, 2013-OCTOBER 2015</i>	158
<i>FIGURE 38 NUMBER OF PATENTS BY ASSIGNEE, 2013-OCTOBER 2015</i>	158
CHAPTER 10 CURRENT SITUATION	160
FACTORS AFFECTING THE PROTEIN THERAPEUTIC MARKET	160
DRIVERS OF THE PROTEIN THERAPEUTIC MARKET	160
Prevalence of Chronic Diseases	160
Growing Aging Population	160
Advancements in Manufacturing Technologies	161
New Product Launches	161
Licensing Agreements	161
RESTRAINTS AND CHALLENGES OF THE MARKET	162
Price Controls	162
Regulatory Pressures	162
Entry of Biosimilars	163
Mergers and Acquisitions	163
CHAPTER 11 COMPANY PROFILES	165
ABBVIE INC.	165
ACTAVIS INC.	165
ALEXION PHARMACEUTICALS	166
ALLERGAN PLC	166
AMGEN INC	167
APOTEX INC.	167
BAXALTA INC	167
BAYER PHARMA AG	168
BIOGEN INC.	168
BIOMARIN PHARMACEUTICAL INC	169

<b>TOPIC</b>	<b>PAGE NO.</b>
BIOTEST PHARMACEUTICALS CORP.	169
BRISTOL-MYERS SQUIBB	170
CSL LIMITED	170
ELI LILLY	171
F. HOFFMANN-LA ROCHE AG	172
FRESENIUS KABI USA	172
GLAXOSMITHKLINE	173
GRIFOLS USA LLC	174
HOSPIRA INC	174
JOHNSON & JOHNSON	175
MEDIMMUNE LLC	175
MERCK & CO, INC	176
MERCK KGAA	177
MYLAN INC.	177
NOVARTIS AG	178
NOVO NORDISK AG	178
OCTAPHARMA AG	179
PFIZER INC	179
PROTEIN SCIENCES CORP.	180
REVO BIOLOGICS INC.	181
SANDOZ	181
SANOFI INC	182
SEATTLE GENETICS INC.	182
SPECTRUM PHARMACEUTICALS INC	183
TAKEDA PHARMACEUTICAL U.S.A., INC	183
UCB COMPANY	184
SHIRE PLC (VIROPHARM INC.)	184
VERTEX PHARMACEUTICALS	185
CHAPTER 12 APPENDIX I - ABBREVIATIONS	187

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL REVENUE FOR PROTEIN DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)	8
TABLE 1 EVOLUTION OF THERAPEUTIC PROTEINS	10
TABLE 2 PROTEIN DRUGS MADE BY FRACTIONATION	24
TABLE 3 THERAPETIC DRUGS PRODUCED BY MICROBIAL FERMENTATION	25
TABLE 4 PROTEIN DRUGS PRODUCED BY TRANSGENIC ANIMALS, PLANTS AND MICROORGANISMS	26
TABLE 5 PROTEIN DRUGS MADE BY CELL CULTURE	27
TABLE 6 NEW APPROVALS OF MONOCLONAL ANTIBODIES, 2013-OCTOBER 2015	29
TABLE 7 NEW APPROVALS IN THERAPEUTIC ENZYMES, 2013-OCTOBER 2015	31
TABLE 8 NEW APPROVALS OF CYTOKINES, 2013-OCTOBER 2015	31
TABLE 9 NEW APPROVALS OF PEPTIDE HORMONES, 2013-OCTOBER 2015	32
TABLE 10 NEW APPROVALS OF VACCINES, 2013-OCTOBER 2015	33
TABLE 11 NEW APPROVALS OF BLOOD PRODUCTS, 2013-OCTOBER 2015	34
TABLE 12 NEW APPROVALS OF PEPTIDE ANTIBIOTICS, 2013-OCTOBER 2015	36
TABLE 13 RECALLS, 2013-OCTOBER 2015	37
TABLE 14 SAFETY ALERTS, 2013-OCTOBER 2015	39
TABLE 15 PIPELINE PRODUCTS OF MONOCLONAL ANTIBODIES	42
TABLE 16 PIPELINE PRODUCTS OF VACCINES	48
TABLE 17 PIPELINE PRODUCTS OF CYTOKINES	50
TABLE 18 PIPELINE PRODUCTS IN PEPTIDE HORMONES	50
TABLE 19 PIEPLINES IN PEPTIDE ANTIBIOTICS	51
TABLE 20 PIPELINE PRODUCTS IN THERAPEUTIC ENZYMES	52
TABLE 21 PIPELINE PRODUCTS IN BLOOD PRODUCTS	53
TABLE 22 MERGERS AND ACQUISITIONS OF TOP PHARMACEUTICAL COMPANIES	54
TABLE 23 GLOBAL REVENUE FOR PROTEIN DRUGS BY TYPE, THROUGH 2020 (\$ MILLIONS)	59
TABLE 24 MARKET SHARE OF PROTEIN DRUGS BY TYPE, 2014 (%)	60
TABLE 25 GLOBAL REVENUE FOR PEPTIDE HORMONES BY TYPE, THROUGH 2020 (\$ MILLIONS)	63
TABLE 26 GLOBAL REVENUE FOR VACCINES BY TYPE, THROUGH 2020 (\$ MILLIONS)	66
TABLE 27 GLOBAL REVENUE FOR THERAPEUTIC ENZYMES BY TYPE, THROUGH 2020 (\$ MILLIONS)	69
TABLE 28 GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY TYPE, THROUGH 2020 (\$ MILLIONS)	73
TABLE 29 GLOBAL REVENUE FOR CYTOKINES BY TYPE, THROUGH 2020 (\$ MILLIONS)	76
TABLE 30 GLOBAL REVENUE FOR BLOOD FACTORS BY TYPE, THROUGH 2020 (\$ MILLIONS)	79
TABLE 31 GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY TYPE, THROUGH 2020 (\$ MILLIONS)	82
TABLE 32 GLOBAL REVENUE FOR PROTEIN DRUGS BY REGION, THROUGH 2020 (\$ MILLIONS)	85
TABLE 33 MARKET SHARE OF PROTEIN DRUGS BY REGION, 2014 (%)	86
TABLE 34 GLOBAL MARKET FOR PEPTIDE HORMONES BY REGION, THROUGH 2020 (\$ MILLIONS)	88
TABLE 35 GLOBAL REVENUE FOR VACCINES BY REGION, THROUGH 2020 (\$ MILLIONS)	91
TABLE 36 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY REGION, THROUGH 2020 (\$ MILLIONS)	93

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 37 GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY REGION, THROUGH 2020 (\$ MILLIONS)	95
TABLE 38 GLOBAL REVENUE FOR CYTOKINES BY REGION, THROUGH 2020 (\$ MILLIONS)	97
TABLE 39 GLOBAL REVENUE FOR BLOOD FACTORS BY REGION, THROUGH 2020 (\$ MILLIONS)	99
TABLE 40 GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY REGION, THROUGH 2020 (\$ MILLIONS)	101
TABLE 41 GLOBAL REVENUE FOR PROTEIN DRUGS BY MANUFACTURING PROCESS, THROUGH 2020 (\$ MILLIONS)	106
TABLE 42 MARKET SHARE OF PROTEIN DRUGS BY MANUFACTURING PROCESS, 2014 (%)	107
TABLE 43 GLOBAL REVENUE FOR PEPTIDE HORMONES BY MANUFACTURING PROCESS, THROUGH 2020 (\$ MILLIONS)	110
TABLE 44 GLOBAL REVENUE FOR VACCINES BY MANUFACTURING PROCESS, THROUGH 2020 (\$ MILLIONS)	112
TABLE 45 GLOBAL REVENUE FOR THERAPEUTIC ENZYMES BY MANUFACTURING PROCESS, THROUGH 2020 (\$ MILLIONS)	115
TABLE 46 GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, THROUGH 2020 (\$ MILLIONS)	117
TABLE 47 GLOBAL REVENUE FOR CYTOKINES BY MANUFACTURING PROCESS, THROUGH 2020 (\$ MILLIONS)	119
TABLE 48 GLOBAL REVENUE FOR BLOOD FACTORS BY MANUFACTURING PROCESS, THROUGH 2020 (\$ MILLIONS)	122
TABLE 49 GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY MANUFACTURING PROCESS, THROUGH 2020 (\$ MILLIONS)	124
TABLE 50 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE HORMONES, 2014	126
TABLE 51 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE HORMONES, 2014 (%)	128
TABLE 52 LEADING MANUFACTURERS/SUPPLIERS OF VACCINES, 2014	129
TABLE 53 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR VACCINES, 2014 (%)	132
TABLE 54 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC ENZYMES, 2014	133
TABLE 55 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR THERAPEUTIC ENZYMES, 2014 (%)	135
TABLE 56 LEADING MANUFACTURERS/SUPPLIERS OF MONOCLONAL ANTIBODIES, 2014	136
TABLE 57 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2014 (%)	137
TABLE 58 LEADING MANUFACTURERS/SUPPLIERS OF CYTOKINES, 2014	138
TABLE 59 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR CYTOKINES, 2014 (%)	139
TABLE 60 LEADING MANUFACTURERS/SUPPLIERS OF THERAPEUTIC BLOOD PRODUCTS, 2014	141
TABLE 61 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR RECOMBINANT BLOOD PRODUCTS, 2014 (%)	143
TABLE 62 LEADING MANUFACTURERS/SUPPLIERS OF PEPTIDE ANTIBIOTICS, 2014	144
TABLE 63 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE ANTIBIOTICS, 2014 (%)	145
TABLE 64 NUMBER OF PATENTS BY YEAR, 2013-OCTOBER 2015	149
TABLE 65 NUMBER OF PATENTS BY TYPE, 2013-OCTOBER 2015	149
TABLE 66 NUMBER OF PATENTS BY COMPANY, 2013-OCTOBER 2015	151

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 67 NUMBER OF PATENTS BY COUNTRY, 2013-OCTOBER 2015	155
TABLE 68 PATENT SHARES BY COUNTRY, 2013-OCTOBER 2015 (%)	156
TABLE 69 NUMBER OF PATENTS BY ASSIGNEE, 2013-OCTOBER 2015	158

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL REVENUE FOR PROTEIN DRUGS BY REGION, 2013-2020 (\$ MILLIONS)	8
FIGURE 1 GLOBAL REVENUE FOR PROTEIN DRUGS BY TYPE, 2013-2020 (\$ MILLIONS)	59
FIGURE 2 MARKET SHARE OF PROTEIN DRUGS BY TYPE, 2014 (%)	60
FIGURE 3 GLOBAL REVENUE FOR PEPTIDE HORMONES BY TYPE, 2013-2020 (\$ MILLIONS)	63
FIGURE 4 GLOBAL REVENUE FOR VACCINES BY TYPE, 2013-2020 (\$ MILLIONS)	67
FIGURE 5 GLOBAL REVENUE FOR THERAPEUTIC ENZYMES BY TYPE, 2013-2020 (\$ MILLIONS)	69
FIGURE 6 GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY TYPE, 2013-2020 (\$ MILLIONS)	74
FIGURE 7 GLOBAL REVENUE FOR CYTOKINES BY TYPE, 2013-2020 (\$ MILLIONS)	77
FIGURE 8 GLOBAL REVENUE FOR BLOOD FACTORS BY TYPE, 2013-2020 (\$ MILLIONS)	79
FIGURE 9 GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY TYPE, 2013-2020 (\$ MILLIONS)	82
FIGURE 10 GLOBAL REVENUE FOR PROTEIN DRUGS BY REGION, 2013-2020 (\$ MILLIONS)	85
FIGURE 11 MARKET SHARE OF PROTEIN DRUGS BY REGION, 2014 (%)	86
FIGURE 12 GLOBAL MARKET FOR PEPTIDE HORMONES BY REGION, 2013-2020 (\$ MILLIONS)	89
FIGURE 13 GLOBAL REVENUE FOR VACCINES BY REGION, 2013-2020 (\$ MILLIONS)	91
FIGURE 14 GLOBAL MARKET FOR THERAPEUTIC ENZYMES BY REGION, 2013-2020 (\$ MILLIONS)	93
FIGURE 15 GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY REGION, 2013-2020 (\$ MILLIONS)	95
FIGURE 16 GLOBAL REVENUE FOR CYTOKINES BY REGION, 2013-2020 (\$ MILLIONS)	98
FIGURE 17 GLOBAL REVENUE FOR BLOOD FACTORS BY REGION, 2013-2020 (\$ MILLIONS)	99
FIGURE 18 GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY REGION, 2013-2020 (\$ MILLIONS)	101
FIGURE 19 GLOBAL REVENUE FOR PROTEIN DRUGS BY MANUFACTURING PROCESS, 2013-2020 (\$ MILLIONS)	106
FIGURE 20 MARKET SHARE OF PROTEIN DRUGS BY MANUFACTURING PROCESS, 2014 (%)	108
FIGURE 21 GLOBAL REVENUE FOR PEPTIDE HORMONES BY MANUFACTURING PROCESS, 2013-2020 (\$ MILLIONS)	110
FIGURE 22 GLOBAL REVENUE FOR VACCINES BY MANUFACTURING PROCESS, 2013-2020 (\$ MILLIONS)	112
FIGURE 23 GLOBAL REVENUE FOR THERAPEUTIC ENZYMES BY MANUFACTURING PROCESS, 2013-2020 (\$ MILLIONS)	115
FIGURE 24 GLOBAL REVENUE FOR MONOCLONAL ANTIBODIES BY MANUFACTURING PROCESS, 2013-2020 (\$ MILLIONS)	117
FIGURE 25 GLOBAL REVENUE FOR CYTOKINES BY MANUFACTURING PROCESS, 2013-2020 (\$ MILLIONS)	120
FIGURE 26 GLOBAL REVENUE FOR BLOOD FACTORS BY MANUFACTURING PROCESS, 2013-2020 (\$ MILLIONS)	122
FIGURE 27 GLOBAL REVENUE FOR PEPTIDE ANTIBIOTICS BY MANUFACTURING PROCESS, 2013-2020 (\$ MILLIONS)	124
FIGURE 28 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE HORMONES, 2014 (%)	128

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
FIGURE 29 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR VACCINES, 2014 (%)	133
FIGURE 30 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR THERAPEUTIC ENZYMES, 2014 (%)	135
FIGURE 31 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR MONOCLONAL ANTIBODIES, 2014 (%)	138
FIGURE 32 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR CYTOKINES, 2014 (%)	139
FIGURE 33 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR RECOMBINANT BLOOD PRODUCTS, 2014 (%)	144
FIGURE 34 MARKET SHARE OF MANUFACTURERS/SUPPLIERS FOR PEPTIDE ANTIBIOTICS, 2014 (%)	145
FIGURE 35 NUMBER OF PATENTS BY YEAR, 2013-OCTOBER 2015	149
FIGURE 36 NUMBER OF PATENTS BY TYPE, 2013-OCTOBER 2015	150
FIGURE 37 PATENT SHARES BY COUNTRY, 2013-OCTOBER 2015 (%)	156
FIGURE 38 NUMBER OF PATENTS BY ASSIGNEE, 2013-OCTOBER 2015	158